In 2014, belinostat (Beleodaq, PXD-101), a hydroxamic acid-type HDAC inhibitor was approved for the treatment of relapsed or refractory PTCL patients [110]. This evidence concerns the gene HDAC9 and mature T-cell and NK-cell non-Hodgkin lymphoma.